Meet The Team 
Leadership That Inspires
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem arcu amet tristique turpis purus, in. Feugiat dictumst eget sem rutrum sem. Vitae, vestibulum vel hendrerit massa duis vehicula et, vulputate.
Franklin Charles
Director of Marketing
Franklin Charles
Director of Marketing
Resources
Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From egnite Data
BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients with severe AS and at least moderate MR. METHODS We analyzed data from 2 992 362 patients (aged ≥18 years) undergoing 5 245 904 echocardiograms at 43 US institutions
Rethinking the Aortic Stenosis Pipeline
Aortic stenosis care is shifting from a reactive to a proactive model. Emerging clinical evidence supports earlier identification, closer monitoring, and intentional patient management across the disease continuum. As treatment thresholds evolve, health systems need scalable approaches to identify at-risk patients, close treatment gaps, and ensure timely access to specialist care.
egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data
The upgrade accelerates a health system’s capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways ALISO VIEJO, Calif. — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage patients with untreated heart disease, today announced significant enhancements to its CardioCare platform, which